The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

BACKGROUND: RRx-001, a dinitroazetidine derivative, is a novel anticancer agent currently in phase II clinical trials. It mediates immunomodulatory effects either directly through polarization of tumor associated macrophages or indirectly through vascular normalization and increased T-lymphocyte inf...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Epigenetics
Päätekijät: Zhao, Hongjuan, Ning, Shoucheng, Nolley, Rosalie, Scicinski, Jan, Oronsky, Bryan, Knox, Susan J., Peehl, Donna M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2017
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5270305/
https://ncbi.nlm.nih.gov/pubmed/28149332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-017-0312-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia